Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy

被引:0
作者
Imai, Hisao [1 ,2 ]
Kobayashi, Daijiro [3 ]
Kaira, Kyoichi [2 ]
Kawashima, Sayaka [4 ]
Masubuchi, Ken [1 ]
Murata, Masumi [3 ]
Ebara, Takeshi [3 ,5 ]
Kitamoto, Yoshizumi [3 ]
Minato, Koichi [1 ]
机构
[1] Gunma Prefectural Canc Ctr, Div Resp Med, 617-1 Takahayashinishi, Ota, Gunma 3738550, Japan
[2] Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, Hidaka, Saitama, Japan
[3] Gunma Prefectural Canc Ctr, Div Radiat Oncol, Ota, Gunma, Japan
[4] Gunma Prefectural Canc Ctr, Div Pharm, Ota, Gunma, Japan
[5] Kyorin Univ, Sch Med, Dept Radiat Oncol, Mitaka, Tokyo, Japan
关键词
chemoradiotherapy; Glasgow prognostic score; locally advanced non-small cell lung cancer; overall survival; post-progression survival; progression-free survival; GLASGOW PROGNOSTIC SCORE; SURROGATE END-POINTS; PHASE-III TRIAL; POSTPROGRESSION SURVIVAL; PERFORMANCE STATUS; TUMOR RESPONSE; CHEMOTHERAPY; THERAPY; METASTASIS; EFFICACY;
D O I
10.2478/raon-2022.0006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The efficacy of first-line chemoradiotherapy for overall survival (OS) might be confounded by the subsequent treatments in patients with locally advanced non-small cell lung cancer (NSCLC). In this study, we assessed the associations of progression-free survival (PFS) and post-progression survival (PPS) with OS after chemoradiotherapy for locally advanced NSCLC using patient-level data. Patients and methods. Between January 2011 and December 2018, 45 patients with locally advanced NSCLC who had received first-line chemoradiotherapy and in whom recurrence occurred were analysed. The associations of PFS and PPS with OS were analysed at the individual level. Results. Linear regression and Spearman rank correlation analyses revealed that PPS was strongly correlated with OS (r = 0.72, p < 0.05, R 2 = 0.54), whereas PFS was moderately correlated with OS (r = 0.58, p < 0.05, R-2 = 0.34). The Glasgow prognostic score and liver metastases at recurrence were significantly associated with PPS (p < 0.001). Conclusions. The current analysis of individual-level data of patients treated with first-line chemoradiotherapy implied that PPS had a higher impact on OS than PFS in patients with locally advanced NSCLC. Additionally, current perceptions indicate that treatment beyond progression after first-line chemoradiotherapy might strongly affect OS.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
    Hiroaki Akamatsu
    Keita Mori
    Tateaki Naito
    Hisao Imai
    Akira Ono
    Takehito Shukuya
    Tetsuhiko Taira
    Hirotsugu Kenmotsu
    Haruyasu Murakami
    Masahiro Endo
    Hideyuki Harada
    Toshiaki Takahashi
    Nobuyuki Yamamoto
    BMC Cancer, 14
  • [42] Neoadjuvant Radiotherapy/Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer
    Yalman, Deniz
    BALKAN MEDICAL JOURNAL, 2015, 32 (01) : 1 - 7
  • [43] Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer
    Shirasawa, Masayuki
    Yoshida, Tatsuya
    Matsumoto, Yuji
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Watanabe, Shun-ichi
    Ohe, Yuichiro
    Motoi, Noriko
    EUROPEAN JOURNAL OF CANCER, 2020, 140 : 28 - 36
  • [44] Emerging Role of Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer
    Mulherkar, Ria
    Grewal, Amardeep S.
    Berman, Abigail T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (04) : 212 - 217
  • [45] Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy
    Xiaoxiang Guan
    Ming Yin
    Qingyi Wei
    Hui Zhao
    Zhensheng Liu
    Li-E Wang
    Xianglin Yuan
    Michael S O'Reilly
    Ritsuko Komaki
    Zhongxing Liao
    BMC Cancer, 10
  • [46] Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy
    Ksienski, Doran
    Truong, Pauline T.
    Bone, Jeffrey N.
    Egli, Sarah
    Clarkson, Melissa
    Patterson, Tiffany
    Lesperance, Mary
    Lakkunarajah, Suganija
    TARGETED ONCOLOGY, 2025, 20 (01) : 149 - 160
  • [47] Post-Progression Survival Highly Influences Overall Survival in Driver Gene Mutation/Translocation Negative or Unknown Type of Non-Small Cell Lung Cancer
    Imai, Hisao
    Onozato, Ryoichi
    Kaira, Kyoichi
    Kawashima, Sayaka
    Masubuchi, Ken
    Tajima, Kohei
    Minato, Koichi
    ONCOLOGY, 2022, 100 (02) : 89 - 100
  • [48] The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer
    Wallace, Neil D.
    Alexander, Marliese
    Xie, Jing
    Ball, David
    Hegi-Johnson, Fiona
    Plumridge, Nikki
    Siva, Shankar
    Shaw, Mark
    Harden, Susan
    John, Tom
    Solomon, Ben
    Officer, Ann
    MacManus, Michael
    LUNG CANCER, 2024, 190
  • [49] Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer
    Hitoshi Ito
    Yukinori Matsuo
    Shuji Ohtsu
    Takashi Nishimura
    Yasuji Terada
    Takashi Sakamoto
    Takashi Mizowaki
    International Journal of Clinical Oncology, 2020, 25 : 274 - 281
  • [50] THE EFFECT OF CHEMORADIOTHERAPY ON SURVIVAL IN LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER PATIENTS: EXPERIENCE FROM THE SOUTHEAST REGION OF TURKEY
    Afsar, Cigdem Usul
    Karaca, Feryal
    Gunaldi, Meral
    Kara, Ismail Oguz
    Erkisi, Melek
    Sahin, Berksoy
    Duman, Berna Bozkurt
    Paydas, Semra
    Ercolak, Vehbi
    ACTA MEDICA MEDITERRANEA, 2015, 31 (04): : 883 - 888